Abstract
Abstract. Amyotrophic lateral sclerosis (ALS) is now still a rare disease that cannot be cured, so patients are in desperate need of medications that can treat the disease. Until now, many researchers have tried to illustrate the pathogenesis of ALS, including misfolded protein aggregation, oxidative stress damage, etc. At the same time, many drugs are in the research phase. However, no consensus has been reached on the pathogenesis of ALS and the drugs on the market can only slow down the process of ALS. This paper firstly investigated researches on the pathogenesis of ALS, and then investigated the possible mechanism of ropinirole, a drug originally used to treat Parkinsons disease (PD) but promising as a treatment for ALS. Meanwhile, the latest clinical trials of ropinirole were reviewed in this paper, suggesting ropinirole could possibly treat ALS through multiple mechanisms including reducing oxidative stress, inducing autophagy, etc. Through investigation, this paper provides theoretical guidance for future studies on the mechanisms of ropinirole in ALS. However, the pathogenic mechanism of ALS and the therapeutic mechanism of ropinirole are not fully understood, especially the pathway of ropinirole in scavenging ROS and regulating the abnormal metabolism of lipids needs further studies.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call